CAR T cells produced in vivo to treat cardiac injury
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 101–200 of 1,001
Fei, Y., Yu, X., Liu, P., Ren, H., Wei, T., & Cheng, Q. (2024) · Advanced Materials · doi:10.1002/adma.202409812 · Cited by 104
Optimizing 5’UTRs for mRNA-delivered gene editing using deep learning
Castillo-Hair, S., Fedak, S., Wang, B., Linder, J., Havens, K., Certo, M., & Seelig, G. (2024) · Nature Communications · doi:10.1038/s41467-024-49508-2 · Cited by 98
Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention
Yin, X., Yin, X., Pan, X., Zhang, J., Fan, X., Li, J., Zhai, X., Jiang, L., Hao, P., Wang, J., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1070973 · Cited by 111
CAR T cells for treating autoimmune diseases
Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D., & Fricke, S. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002907 · Cited by 98
Poss, K. D., & Tanaka, E. M. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.07.007 · Cited by 109
Frameworks for transformational breakthroughs in RNA-based medicines
Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 108
Cell type-specific delivery by modular envelope design
Strebinger, D., Frangieh, C. J., Friedrich, M., Faure, G., Macrae, R. K., & Zhang, F. (2023) · Nature Communications · doi:10.1038/s41467-023-40788-8 · Cited by 99
mRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 99
Stranford, D. M., Simons, L. M., Berman, K. E., Cheng, L., DiBiase, B. N., Hung, M. E., Lucks, J. B., Hultquist, J. F., & Leonard, J. N. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01142-x · Cited by 100
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 102
Pinto, E., Lione, L., Compagnone, M., Paccagnella, M., Salvatori, E., Greco, M., Frezza, V., Marra, E., Aurisicchio, L., Roscilli, G., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06052-3 · Cited by 100
In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice
Nahmad, A. D., Lazzarotto, C. R., Zelikson, N., Kustin, T., Tenuta, M., Huang, D., Reuveni, I., Nataf, D., Raviv, Y., Horovitz‐Fried, M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01328-9 · Cited by 97
From thymus to tissues and tumors: A review of T-cell biology
Chopp, L. B., Redmond, C., O’Shea, J. J., & Schwartz, D. M. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.10.011 · Cited by 108
Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications
Chan, A., & Tsourkas, A. (2023) · BME Frontiers · doi:10.34133/bmef.0035 · Cited by 99
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Kong, Y., Li, J., Zhao, X., Wu, Y., & Chen, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1519671 · Cited by 119
Chen, M. Z., Yuen, D., McLeod, V. M., Yong, K. W., Smyth, C. H., Herling, B. R., Payne, T. J., Fabb, S. A., Belousoff, M. J., Algarni, A., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01954-9 · Cited by 113
Lipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 106
Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA
Hashiba, K., Sato, Y., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Shishido, T., Murakawa, M., Arimichi, O., & Harashima, H. (2022) · Small Science · doi:10.1002/smsc.202200071 · Cited by 113
Biomimetic noncationic lipid nanoparticles for mRNA delivery
Wang, C., Zhao, C., Wang, W., Liu, X., & Deng, H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2311276120 · Cited by 93
CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury
Wang, J., Du, H., Xie, W., Bi, J., Zhang, H., Liu, X., Wang, Y., Zhang, S., Lei, A., He, C., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.325212 · Cited by 93
Andorko, J. I., Russell, R. M., Schnepp, B. C., Grubaugh, D., Mullen, K. F., Wakabayashi, A., Carrington, L. J., O’Malley, T. M., Kuri-Cervantes, L., Culp, T. D., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.036 · Cited by 102
Polymer- and lipid-based gene delivery technology for CAR T cell therapy
Pinto, I. S., Cordeiro, R. A., & Faneca, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.038 · Cited by 96
Liang, G., Cao, W., Tang, D., Zhang, H., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · ACS Nano · doi:10.1021/acsnano.3c11154 · Cited by 89
Chimeric antigen receptor therapy meets mRNA technology
Wu, J., Wu, W., Zhou, B., & Li, B. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.08.005 · Cited by 91
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 121
Living Leukocyte‐Based Drug Delivery Systems
Chen, Y., Qin, D., Zou, J., Li, X., Guo, X. D., Tang, Y., Chuang, L. I. U., Chen, W., Kong, N., Zhang, C. Y., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207787 · Cited by 97
Targeted nonviral delivery of genome editors in vivo
Tsuchida, C. A., Wasko, K. M., Hamilton, J. R., & Doudna, J. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307796121 · Cited by 90
Immune-Epithelial Cross Talk in Regeneration and Repair
Guenin‐Macé, L., Konieczny, P., & Naik, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-062818 · Cited by 87
Cationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart
Radmand, A., Kim, H., Beyersdorf, J. P., Dobrowolski, C. N., Zenhausern, R., Paunovska, K., Huayamares, S. G., Hua, X., Han, K., Loughrey, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307801120 · Cited by 88
Sanchez, A. J. D. S., Loughrey, D., Echeverri, E. S., Huayamares, S. G., Radmand, A., Paunovska, K., Hatit, M. Z. C., Tiegreen, K. E., Santangelo, P. J., & Dahlman, J. E. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304033 · Cited by 90
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 96
McKinsey, T. A., Foo, R., Anene-Nzelu, C. G., Travers, J. G., Vagnozzi, R. J., Weber, N., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac142 · Cited by 90
Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery
Gan, Z., Xue, L., Geisler, H. C., Xu, J., Li, X., Mitchell, M. J., & Vaughan, A. E. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314747121 · Cited by 92
Sequential immunotherapy: towards cures for autoimmunity
Ramírez‐Valle, F., Maranville, J., Roy, S., & Plenge, R. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00959-8 · Cited by 85
Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy
Metzloff, A. E., Padilla, M. S., Gong, N., Billingsley, M. M., Han, X., Merolle, M. I., Mai, D. H., Figueroa‐Espada, C. G., Thatte, A. S., Haley, R. M., et al. (2024) · Advanced Materials · doi:10.1002/adma.202313226 · Cited by 112
Self-citationNucleic acid therapeutics: Past, present, and future
Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 91
Emerging frontiers in regenerative medicine
McKinley, K. L., Longaker, M. T., & Naik, S. (2023) · Science · doi:10.1126/science.add6492 · Cited by 88
Systematic Review of Available CAR-T Cell Trials around the World
Barros, L. R. C., Couto, S. C. F., da Silva Santurio, D., Paixão, E. A., Cardoso, F., da Silva, V. J., Klinger, P., Ribeiro, P. D. A. C., Rós, F. A., Oliveira, T. G. M., et al. (2022) · Cancers · doi:10.3390/cancers14112667 · Cited by 76
Sánchez‐Martínez, D., Tirado, N., Mensurado, S., Martínez‐Moreno, A., Romecín, P. A., Gutiérrez‐Agüera, F., Correia, D. V., Silva‐Santos, B., & Menéndez, P. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005400 · Cited by 79
Paunovska, K., Sanchez, A. J. D. S., Lokugamage, M. P., Loughrey, D., Echeverri, E. S., Cristian, A., Hatit, M. Z. C., Santangelo, P. J., Zhao, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03741 · Cited by 80
mRNA therapeutics: New vaccination and beyond
Wei, H. Y., Zheng, L., & Wang, Z. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.02.022 · Cited by 81
Ji, X., Meng, Y., Wang, Q., Tong, T., Liu, Z., Lin, J., Li, B., Wei, Y., You, X., Lei, Y., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c10042 · Cited by 80
Naidu, G. S., Rampado, R., Sharma, P., Ezra, A., Kundoor, G. R., Breier, D., & Peer, D. (2025) · ACS Nano · doi:10.1021/acsnano.4c18636 · Cited by 82
Tissue-specific mRNA delivery and prime editing with peptide–ionizable lipid nanoparticles
Lin, Y., Li, M., Luo, Z., Meng, Y., Zong, Y., Ren, H., Yu, X., Tan, X., Liu, F., Wei, T., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02320-9 · Cited by 97
Dual genetic tracing reveals a unique fibroblast subpopulation modulating cardiac fibrosis
Han, M., Liu, Z., Liu, L., Huang, X., Wang, H., Pu, W., Wang, E., Liu, X., Li, Y., He, L., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01337-7 · Cited by 80
Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond
Lin, Y., Cheng, Q., & Wei, T. (2023) · Biophysics Reports · doi:10.52601/bpr.2023.230022 · Cited by 82
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 96
Hofstraat, S. R. J., Anbergen, T., Zwolsman, R. C., Deckers, J., van Elsas, Y., Trines, M. M., Versteeg, I., Hoorn, D., Ros, G. W. B., Bartelet, B. M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01847-3 · Cited by 89
Inflammatory Mechanisms in Heart Failure with Preserved Ejection Fraction
Daou, D., Gillette, T. G., & Hill, J. A. (2023) · Physiology · doi:10.1152/physiol.00004.2023 · Cited by 95
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., & Zhou, D. (2023) · Cancers · doi:10.3390/cancers15133476 · Cited by 83
Li, X., Gong, N., Tian, F., Zhang, S., Zhang, Y., Wang, Y., Qing, G., Wang, Y., Li, F., Xu, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01084-4 · Cited by 81
mRNA: A promising platform for cancer immunotherapy
Kong, B., Kim, Y., Kim, E. H., Suk, J. S., & Yang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114993 · Cited by 86
Biomaterials for in situ cell therapy
Wang, C., Wang, S., Kang, D. D., & Dong, Y. (2023) · BMEMat · doi:10.1002/bmm2.12039 · Cited by 74
Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape
Zhai, Y., Du, Y., Li, G., Yu, M., Hu, H., Pan, C., Wang, D., Shi, Z., Yan, X., Li, X., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01708-w · Cited by 86
Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application
Mashima, R., & Takada, S. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100341 · Cited by 78
Lipid nanoparticles for mRNA delivery
Tanaka, H., Sakurai, Y., & Akita, H. (2022) · Drug Delivery System · doi:10.2745/dds.37.237 · Cited by 74
Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease
Caporali, A., Anwar, M., Devaux, Y., Katare, R., Martelli, F., Srivastava, P. K., Pedrazzini, T., & Emanueli, C. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01001-5 · Cited by 77
Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis
Qian, H., Deng, C., Chen, S., Zhang, X., He, Y., Lan, J., Wang, A., Shi, G., & Liu, Y. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03343-4 · Cited by 78
Designing drug delivery systems for cell therapy
Wang, L., Gao, Y., Feng, Z., Mooney, D. J., & Mitragotri, S. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00214-0 · Cited by 94
Structure and Morphology of Lipid Nanoparticles for Nucleic Acid Drug Delivery: A Review
Udepurkar, A. P., Devos, C., Sagmeister, P., Destro, F., Inguva, P., Ahmadi, S., Boulais, É., Quan, Y., Braatz, R. D., & Myerson, A. S. (2025) · ACS Nano · doi:10.1021/acsnano.4c18274 · Cited by 77
Pei, J., Cai, L., Wang, F., Xu, C., Pei, S., Guo, H., Sun, X., Chun, J. J. M., Cong, X., Zhu, W., et al. (2022) · Circulation Research · doi:10.1161/circresaha.122.321036 · Cited by 73
RNA Therapeutics for the Cardiovascular System
Dzau, V. J., & Hodgkinson, C. P. (2024) · Circulation · doi:10.1161/circulationaha.123.067373 · Cited by 79
Design and translation of injectable biomaterials
Nguyen, M., Karkanitsa, M. L., & Christman, K. L. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00213-1 · Cited by 81
Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics
Vasileva, O., Zaborova, O. V., Shmykov, B., Ivanov, R. A., & Reshetnikov, V. V. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1466337 · Cited by 86
In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles
Zhao, G., Zhang, Y., Xu, C., & Wang, J. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.11.055 · Cited by 73
A coalition to heal—the impact of the cardiac microenvironment
Tzahor, E., & Dimmeler, S. (2022) · Science · doi:10.1126/science.abm4443 · Cited by 68
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
Hovhannisyan, L., Riether, C., Aebersold, D. M., Medová, M., & Zimmer, Y. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01775-1 · Cited by 74
González, A., López, B., Ravassa, S., José, G. S., Latasa, I., Butler, J., & Díez, J. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21708 · Cited by 74
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68
Breaking the mold with RNA—a “RNAissance” of life science
Jones, C. H., Androsavich, J. R., So, N., Jenkins, M. P., MacCormack, D., Prigodich, A. E., Welch, V., True, J. M., & Dolsten, M. (2024) · npj Genomic Medicine · doi:10.1038/s41525-023-00387-4 · Cited by 73
Microfluidic Nanoparticle Separation for Precision Medicine
Lan, Z., Chen, R., Zou, D., & Zhao, C. (2024) · Advanced Science · doi:10.1002/advs.202411278 · Cited by 76
Clinical development of therapeutic mRNA applications
Żak, M. M., & Zangi, L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.034 · Cited by 79
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Scherlinger, M., Nocturne, G., Radic, M. Z., Launay, D., Richez, C., Bousso, P., Forcade, É., Meyer, A., Jørgensen, C., Bigenwald, C., et al. (2025) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00377-1 · Cited by 75
Immune cells in cardiac repair and regeneration
Simões, F. C., & Riley, P. R. (2022) · Development · doi:10.1242/dev.199906 · Cited by 71
Advanced delivery systems for peptide antibiotics
Cesaro, A., Lin, S., Pardi, N., & de la Fuente‐Núñez, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114733 · Cited by 75
Programmable synthetic receptors: the next-generation of cell and gene therapies
Teng, F., Cui, T., Zhou, L., Gao, Q., Zhou, Q., & Li, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01680-5 · Cited by 88
Emerging molecular imaging targets and tools for myocardial fibrosis detection
Barton, A. K., Tzolos, E., Bing, R., Singh, T., Weber, W., Schwaiger, M., Varasteh, Z., Slart, R. H. J. A., Newby, D. E., & Dweck, M. R. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac242 · Cited by 68
Biomaterials to enhance adoptive cell therapy
Eckman, N., Nejatfard, A., Cavet, R., Grosskopf, A. K., & Appel, E. A. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00148-z · Cited by 69
Engineering strategies to safely drive CAR T-cells into the future
Rossi, M., & Breman, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411393 · Cited by 72
Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism
Li, Z., Amaya, L., Pi, R., Wang, S. K., Ranjan, A., Waymouth, R. M., Blish, C. A., Chang, H. Y., & Wender, P. A. (2023) · Nature Communications · doi:10.1038/s41467-023-42672-x · Cited by 75
Functional diversity of cardiac macrophages in health and disease
Yang, S. H., Penna, V. R., & Lavine, K. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01109-8 · Cited by 72
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 68
Progress and prospect of nanotechnology for cardiac fibrosis treatment
Gaytan, S. L., Beaven, E., Gadad, S. S., & Nurunnabi, M. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230018 · Cited by 66
CAR-T cell therapy: Where are we now, and where are we heading?
Wang, J., & Wang, L. (2023) · Blood Science · doi:10.1097/bs9.0000000000000173 · Cited by 71
Next-generation materials for nucleic acid delivery
van der Meel, R., Wender, P. A., Merkel, O. M., Lostalé‐Seijo, I., Montenegro, J., Miserez, A., Laurent, Q., Sleiman, H. F., & Luciani, P. (2025) · Nature Reviews Materials · doi:10.1038/s41578-025-00814-1 · Cited by 73
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications
Zou, A. E., Kongthong, S., Mueller, A. A., & Brenner, M. B. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01259-0 · Cited by 68
Engineered multi-domain lipid nanoparticles for targeted delivery
Liu, Z., Chen, J., Xu, M., Ho, S., Wei, Y., Ho, H., & Yong, K. (2025) · Chemical Society Reviews · doi:10.1039/d4cs00891j · Cited by 70
Yan, J., Wang, S.-Y., Su, Q., Zou, M.-W., Zhou, Z.-Y., Shou, J., & Huo, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-59093-7 · Cited by 62
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 65
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 71
A Review on the Stability Challenges of Advanced Biologic Therapeutics
Sarvepalli, S., Pasika, S. R., Verma, V., Thumma, A., Bolla, S., Nukala, P. K., Butreddy, A., & Bolla, P. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050550 · Cited by 69
Engineered natural killer cells for cancer therapy
Biederstädt, A., & Rezvani, K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.013 · Cited by 69
Extracellular vesicles as next generation immunotherapeutics
Greening, D. W., Xu, R., Ale, A., Hagemeyer, C. E., & Chen, W. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.002 · Cited by 62
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 65
Systematic discovery of CRISPR-boosted CAR T cell immunotherapies
Datlinger, P., Pankevich, E. V., Arnold, C. D., Pranckevicius, N., Lin, J., Romanovskaia, D., Schaefer, M., Piras, F., Orts, A.-C., Nemc, A., et al. (2025) · Nature · doi:10.1038/s41586-025-09507-9 · Cited by 69
Inflammation and Atherosclerosis: Prospects for Clinical Trials
Ait‐Oufella, H., & Libby, P. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320155 · Cited by 63
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Lee, I. K., Noguera-Ortega, E., Xiao, Z., Todd, L., Scholler, J., Song, D., Liousia, M., Lohith, K., Xu, K., Edwards, K. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1379 · Cited by 61
Self-citationVornholz, L., Isay, S. E., Kurgyis, Z., Strobl, D. C., Loll, P., Mosa, M. H., Luecken, M. D., Sterr, M., Lickert, H., Winter, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.add8564 · Cited by 62
Myocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact
Lunde, I. G., Rypdal, K. B., Linthout, S. V., Díez, J., & González, A. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.08.008 · Cited by 68
Wang, W., Hu, K., Xue, J., Chen, J., Du, X., Zhao, T., Chen, Y., Tang, X., Lü, X. C., Hao, X., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113888 · Cited by 64
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.